Immunovative Therapies is a biopharmaceutical company with financial support of the Israel Office of the Chief Scientist. ITL is a graduate of the Misgav Venture Accelerator, a member of the world renown Israel technological incubator program. The company was the Misgav Venture Accelerator's candidate for the prize for the outstanding incubator project of 2006, awarded by the Office of the Chief Scientist. They specialize in the development of novel immunotherapy drug products that incorporate living immune cells as the active ingredients for the treatment of cancer and infectious disease.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Carina Biotech is a biotechnology company that develops cellular immunotherapies, particularly to treat childhood cancers. They research and develop chimeric antigen receptor T cell (CAR-T) therapies to treat solid cancers. They develop technologies to improve access to and infiltration of solid cancers and enhance CAR-T cell manufacturing.

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

MicroMedMark develops basic research, applied basic research, transformation research, and a biomedical technology enterprise for industrial transformation. Their products and services include a pancreatic cancer detection kit, a detection kit product pipeline, and nucleic acid.

IMTM GmbH is engaged in the development of therapeutic drugs for the treatment of immune dysfunction diseases and conditions. The firm specializes in silico, in vitro, and in vivo methods that focus on the discovery, optimization, and analysis of drug candidates. Its service areas encompass drug design, pharmaceutical development, experimental medicine research, clinical trials, and laboratory testing. The company was founded in 1996 and is headquartered in Magdeburg, Germany.

Alligator Bioscience is an innovative research based biotech company focused on developing novel drugs for immunotherapy of cancer. Alligator discovers and develops drug development candidates up to phase IIa clinical studies. Alligator’s pipeline currently counts three immune-modulating projects, ADC-1013, ADC-1015, and ADC-1016. Alligator uses its proprietary technology platforms: ALLIGATOR-GOLD, a unique fully human antibody library, and FIND® (Fragment INduced Diversity), a powerful in vitro based antibody optimization technology, in growing our pipeline.

St. Vincent's Hospital Sydney Pty Ltd. provides health services. It offers cardiology, dental, endocrinology, audiology, mental health, medicine, sacred heart health services, urology, and vascular surgery. The company was founded in 1857 and is headquartered in Darlinghurst, Australia.

Korea Food Research Institute is a global food R&D institution that contributes to the health of Korea.

Virginia Tech Intellectual Properties, Inc. handles, protects and licenses technologies developed by the faculty, staff and students. It facilitates the licensing of technology to companies, encourages new faculty startup ventures, works with publishers and distributors of software, and supports the transfer of research and knowledge to other universities, research institutes and companies. The company was founded in 1985 and is headquartered in Blacksburg, VA.

Acetylon Pharmaceuticals, Inc. develops pharmaceutical technology. It develops novel small molecule drugs which targets epigenetic mechanisms for the enhancement of therapeutic outcomes in cancer and other critical human diseases. The company was founded by Ralph Mazitschek, Kenneth C. Anderson, Marc A. Cohen, James E. Bradner, and Walter C. Ogier in October 2008 and is headquartered in Boston, MA.

Jiangsu Province Hospital of Traditional Chinese Medicine is a Chinese private company located in Nanjing. The firm provides medical services.

Adelaide Research & Innovation Pty Ltd., part of University of Adelaide, is a company headquartered in Adelaide, Australia, that provides analytical research services. Robert Chalmers is the current CEO of the firm.

Jian Duo Shiguang (Beijing) Technology Co., Ltd., established on 2017-07-19, Business scope includes technology development,Technical Services,Technology Promotion,technical consulting;technology transfer;Sell ​​self-developed products;Computer System Services;Basic software service;Application software service;software development;software consulting;product design;model design;Natural science research and experimental development;Medical Research and Experimental Development;Undertake exhibition and display activities;Conference Services;buisness planning.(Enterprises independently choose operating projects according to law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

Apellis Pharmaceuticals is an early-stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease. The company is leveraging courageous science, creativity, and compassion to deliver life-changing medicines. They aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. It was founded in 2008 and headquartered in Waltham, Massachusetts, United States.

Argos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83 soluble protein for transplant rejection/autoimmune disorders; Anti IFN-alpha monoclonal antibody2 for lupus; and regulatory T cell therapy3 for autoimmune disorders. The company was formerly known as MERIX Bioscience, Inc. Argos Therapeutics was founded in 1997 and is based in Durham, North Carolina.

TxCell, a spin off of Inserm (France's National Institute for Health and Medical Research) located in the technology park of Sophia Antipolis, near Nice in southern France, is developing cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases with high medical need using its unique and proprietary technology platform based on the properties of Type 1 regulatory T lymphocytes (Tr1 cells). The company has completed enrollment of a PhI/II study in refractory Crohn's disease patients and has reported first positive results. The company plans to initiate a PhIIb study in the same patient population and bring a second product candidate into a PhI/II study in refractory rheumatoid arthritis patients.

Cancer Research Ventures Ltd. engages in the business of research and experimental development on biotechnology. It provides medical products. The company is headquartered in London, the United Kingdom.